White Paper Explores the Amarantus Bioscience Alzheimer’s Disease Diagnostic

Amarantus Bioscience has posted a White Paper exploring the company’s LymPro Alzheimer’s Disease diagnostic, prepared by a member of the company’s Board of Advisors.

The Paper discusses the increasing prevalence of Alzheimer’s disease, the clinical and economic advantages of early detection, and why the LymPro Test is poised to potentially become the market leading diagnostic product in the Alzheimer’s space. Adam J. Simon, Ph.D., the preparer of the White Paper, is regarded as an expert in working with Alzheimer’s disease biomarkers, and also has significant expertise in the development of in-vitro diagnostics.

Amarantus built a diagnostics platform through the late-2012 acquisition of the Lympro test and NuroPro, a blood test for Parkinson’s Disease detection.

LymPro will be evaluated for commercial use in early detection of Alzheimer’s, as well as a companion diagnostic and use in clinical development. The LymPro trial has enrolled more than 160 patients, and Commissiong noted in the company’s shareholder update call in April that the company plans to verify previous published studies in the coming months. The company will also initiate a third study at the same independent laboratory to support worldwide sales, which will help to secure certification in the US.

Amarantus believes that LymPro could be a $900 million market opportunity approved as a companion diagnostic product, in addition to a commercial diagnostic which could be valued in the $10BNs. LymPro could also move the diagnostic paradigm, as the test may also yield the diagnosis of mild cognitive impairment and pre-dementia Alzheimer’s.

The White Paper explores the scientific underpinnings of the LymPro test.

**Click to view the White Paper**

The comments are closed.